MOTS-c: A Signal Encoded Inside the Mitochondrion

The short version

MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA type-c. Its sequence — MRWQEMGYIFYPRKLR — is encoded not in the nucleus, where nearly all human genes live, but inside the mitochondrial genome. That origin is biologically significant: mitochondria are the cell's power plants, and a peptide that they themselves encode can signal back to the nucleus about the cell's energy state, a type of communication called retrograde signaling ^[5].

What MOTS-c does, in plain terms: it disrupts a specific metabolic shortcut (the folate cycle), which raises a signaling molecule called AICAR, which in turn activates AMPK — the master energy-sensing kinase that tells the cell to burn fuel more efficiently and take up glucose from the blood ^[6]. In aged mice, injecting exogenous MOTS-c significantly improved running capacity and grip strength ^[4]. In a human observational study of 94 hemodialysis patients, circulating MOTS-c levels independently predicted cardiovascular events and all-cause mortality ^[2].

The important caveat: every claim about MOTS-c improving anything in living systems comes from animal studies or cell experiments. The human data are observational only — they show that MOTS-c levels in blood associate with outcomes, not that exogenous MOTS-c does anything in people. No human dosing, efficacy, or safety trials have been completed. This page summarizes what was studied; it is not advice and lists no human dose.

What it is

MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA gene (MT-RNR1). It belongs to a growing class of molecules called mitochondrial-derived peptides (MDPs) — short peptides translated from mitochondrial DNA rather than nuclear DNA, which appear to function as stress-responsive signals between the mitochondrion and the rest of the cell.

The peptide is highly conserved across mammalian species and is endogenously present in human blood. Levels rise with exercise ^[4] and vary with age, ancestry and metabolic state. MOTS-c is a research chemical: it is not approved by the FDA for any use, not manufactured under pharmaceutical-grade conditions for human use, and not approved as a drug or supplement anywhere.

How it works

The best-characterized mechanism begins in an unexpected place: not a receptor on the cell surface, but a metabolic pathway inside the cell. MOTS-c inhibits two enzymes of the folate cycle and de novo purine biosynthesis. That inhibition causes AICAR — a natural AMPK activator — to accumulate, which activates AMPK in skeletal muscle and improves glucose uptake and insulin sensitivity ^[6]. AMPK is sometimes called the cell's fuel-gauge: when energy is low, AMPK switches off ATP-consuming processes and switches on fuel burning.

Under metabolic stress, MOTS-c does something unusual for a mitochondrially-encoded peptide: it leaves the mitochondrion, travels to the nucleus, and directly regulates nuclear gene expression. A 2018 study showed this translocation is AMPK-dependent and includes activation of antioxidant-response genes via NRF2, an important stress-defense transcription factor ^[5]. This makes MOTS-c the first demonstrated example of retrograde mitochondrion-to-nucleus signaling by a mitochondrially-encoded peptide.

A 2024 study identified casein kinase 2 (CK2) as a direct molecular target: MOTS-c binds and modulates CK2 in a tissue-specific manner (activating it in muscle, suppressing it in fat), which underlies its effects on muscle glucose uptake and atrophy prevention ^[1].

What the research shows

Founding mechanism. The peptide was identified in 2015: a 16-amino-acid peptide from MT-RNR1 that inhibits the folate cycle, activates AMPK, and in mice prevented diet-induced obesity and insulin resistance and improved age-related insulin sensitivity ^[6]. This study established skeletal muscle as the primary target organ.

Exercise inducibility and aging. A 2021 study showed that MOTS-c is released by exercising muscle and rises in blood with exertion. Exogenous MOTS-c injected into mice of different ages improved physical performance significantly — for aged mice (22-23.5 months), treadmill capacity, grip strength and gait all improved with a p-value of 0.000002 ^[4]. The result positions MOTS-c as a candidate exercise-mimetic molecule, potentially explaining part of why exercise benefits metabolic and physical function with age.

Nuclear translocation. Under metabolic stress (AICAR treatment or glucose deprivation), MOTS-c enters the nucleus and shifts gene expression in an AMPK-dependent manner, including antioxidant-response-element (ARE) genes via interaction with NRF2 ^[5]. This was the first demonstrated nuclear function of any mitochondrially-encoded peptide.

Direct molecular target. A 2024 study using cell-free assays and multiple mouse models (young, aged, high-fat-diet, and immobilized) showed MOTS-c directly binds CK2, identified it as the proximal effector, and linked tissue-specific CK2 modulation to prevention of skeletal muscle atrophy and enhanced glucose uptake ^[1].

Diabetic heart. In a rat model of type-2 diabetes (high-fat diet plus streptozotocin), MOTS-c treatment increased mitochondrial respiratory (OXPHOS) capacity in cardiac tissue and was associated with lower fasting glucose and reduced left-ventricular hypertrophy ^[7].

Human biomarker data. A 2024 multicenter cohort followed 94 chronic hemodialysis patients for a median of 26.5 months. Baseline circulating MOTS-c independently predicted a composite endpoint of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05); adding MOTS-c to a standard risk model improved AUC from 0.727 to 0.743 ^[2]. A comprehensive 2023 review consolidated the mechanistic and translational picture across metabolic, stress-adaptive and aging pathways ^[3].

Reported effects, cautions & safety

MOTS-c has no community-reported anecdote record compiled in this desk's source material, so none is presented here. The cautions below are drawn directly from the cited literature.

• No human efficacy trials. Every claim about exogenous MOTS-c improving metabolism, performance or aging comes from cell or animal studies. Human data are observational biomarker associations, not interventional outcomes.
• No validated human pharmacokinetics. There is no published, measured human half-life, bioavailability or dose-response. Rodent doses (0.5-15 mg/kg/day in various experiments) cannot be extrapolated to humans.
• Research-chemical status. MOTS-c is not approved by the FDA for any use and is sold only for laboratory research. Product purity, identity and sterility vary by supplier and are not regulated as pharmaceuticals.
• Anti-doping prohibition. MOTS-c is treated as a prohibited peptide in elite sport under WADA/USADA hormone-and-metabolic-modulator categories. Athletes face sanctions for use.
• Population-specific effects. A pro-diabetogenic MOTS-c mtDNA variant (m.1382A>C) and ancestry-dependent exercise responses suggest effects are not uniform across populations.
• Marketplace claims outpace evidence. Consumer interest in fat loss, longevity and performance greatly exceeds the strength of the clinical evidence. This literature digest exists to contextualize that gap.

Where it fits in longevity research

Among the two compounds on this desk, MOTS-c is the lead and the more unusual: a peptide that the mitochondrion itself makes and uses to communicate with the nucleus about the cell's energy state. Its animal record spans metabolic regulation, muscle aging and cardiac function, unified by an AMPK-and-mitochondrial-signaling story; its human file is observational only ^[2][3]. Read alongside NAD+ — the energy currency that AMPK helps manage — MOTS-c illustrates the central tension of the whole longevity-peptide field: a coherent, mechanistically rich preclinical signal that has barely crossed into controlled human work. See the comparison page for how it lines up against NAD+.